So, we are here, he said, pointing to a slide
In particular, investors are increasingly distinguishing between companies whose AI capabilities merely improve discovery efficiency and those that can demonstrate those capabilities translate into differentiated therapeutic assets, reproducible validation, and a credible path into the clinic
Regulating Semaglutide works by mimicking the body's response to hunger
Novel material-based approaches are also being investigated to advance pulmonary drug delivery, such as thin-film freezing, supercritical fluid technology, nano-in-micro particle systems, crystal-engineered microstructures, and porous drug carriers, all of which aim to improve drug stability, bioavailability, and pulmonary retention [209, 210]
Clinical trial results for retatrutide have exceeded even the high expectations set by tirzepatide, with Phase 2 data published in the New England Journal of Medicine in 2023 demonstrating weight loss approaching 24-25% of baseline body weight over 48 weeks in some dose groups - weight reductions comparable to those achieved with bariatric surgery and substantially exceeding pharmacological obesity treatments available just a few years ago
*P 0.05 versus NC group